Patents Examined by Lawrence E. Crane
  • Patent number: 11344565
    Abstract: Provided are methods of preparing compounds and pharmaceutical compositions comprising a compound Formula VIII for treating Filoviridae virus infections. In one aspect, the compound of Formula VIII is formed from a reaction mixture comprising the compound of Formula IX, the compound of Formula X, a coupling agent such as magnesium chloride and a non-nucleophilic base such as diisopropylethylamine. The compound of Formula IX can be formed from a compound of Formula V and a cyanating agent. The compound of Formula V can be synthesized from a reaction mixture comprising a deprotonating agent such as phenylmagnesium chloride; a silylating agent such as chlorotrimethylsilane; a coupling agent such as isopropylmagnesium chloride, an additive such as LaCl3-2LiCl, LaCl3, CeCl3, NdCl3, or YCl3; a compound of Formula VI; and 7-iodopyrrolo[2,1-f][1,2,4]triazin-4-amine. The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 31, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Steven Donald Axt, Pavel Robertovich Badalov, Katrien Brak, Silvio Campagna, Andrei Chtchemelinine, Edward Doerffler, Morin Mae Frick, Detian Gao, Lars V. Heumann, Brittanie Hoang, Willard Lew, Robert Ronald Milburn, Sean Timothy Neville, Bruce Ross, Erik Rueden, Robert William Scott, Dustin Siegel, Andrew C. Stevens, Clarissa Tadeus, Tiago Vieira, Andrew W. Waltman, Xianghong Wang, Mark Charles Whitcomb, Lydia Wolfe, Chia-Yun Yu
  • Patent number: 11324768
    Abstract: There is provided herein a method of treating and/or alleviating vascular inflammation or vascular endothelial function disorders comprising administering 2?,3,? 5?-triacetyl-N6(3-hydroxyphenyl)adenosine of formula (I): such as in the form of a pharmaceutical composition, to a person suffering from vascular inflammation or vascular endothelial function disorders.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: May 10, 2022
    Assignees: JIANGSU TASLY DIYI PHARMACEUTICALS CO., LTD., INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Haibo Zhu, Minjie Wang
  • Patent number: 11318157
    Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: May 3, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • Patent number: 11286274
    Abstract: The disclosure provides derivatives of both the oxidized form and the reduced form of nicotinamide riboside (NR) and nicotinic acid riboside (NAR). The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR, and can increase cellular NAD+ levels and improve mitochondrial function. Therefore, the NR and NAR derivatives are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, and other disorders and conditions.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: March 29, 2022
    Assignee: MitoPower LLC
    Inventors: Gangadhara Ganapati, Atignal Shankara Rao Arvind
  • Patent number: 11268094
    Abstract: The present invention provides 5? modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5?-substituent and an optional 2? substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: March 8, 2022
    Assignee: Ionis Pharmaceuticals, Inc
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 11267843
    Abstract: Stereodefined phosphorothioate oligonucleotides, related nucleoside monomers and methods of synthesis of both are described. The disclosed isobutyryl protected L-LNA-G monomers have following Formula 50 or 51 where R3 is independently CH2ODMTr or CH2OMMTr and R8, when present, is cyanoethyl. The monomers have improved solubility and stability characteristics, resulting in improved efficacy in oligonucleotide synthesis.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: March 8, 2022
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Jacob Ravn, Erik Daa Funder
  • Patent number: 11261209
    Abstract: The present invention relates to the synthesis of stereo-defined phosphorothioate oligonucleotides of formula I: Wherein Z, R1, R5, R6 and R9 are as defined herein. Phosphorothioate oligonucleotides are useful as therapeutics.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: March 1, 2022
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Jacob Ravn, Erik Daa Funder
  • Patent number: 11260070
    Abstract: Provided are methods of treating feline Coronavirus infections using carbanucleoside compounds having a 1?-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl) substituent, or a pharmaceutically acceptable salt thereof. An exemplary compound is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: March 1, 2022
    Assignees: Gilead Sciences, Inc., The Regents of the University of California
    Inventors: Michel Joseph Perron, Niels C Pedersen
  • Patent number: 11253535
    Abstract: A method of treating Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), a cardiomyopathy or a muscular traumatism in a subject includes administering to the subject certain ADP ribosylcyclase antagonist compounds, certain cyclic ADP ribose (cADPR) antagonist compounds, certain nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist compounds or a mixture of these compounds.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 22, 2022
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: José-Manuel Cancela, Sabine De La Porte, Antoine De Zelicourt
  • Patent number: 11208430
    Abstract: The present invention is directed to modified oligonucleotides having the following Formula (I) wherein one or more of phosphate groups are substituted at phosphorus, and methods for their synthesis. The modified oligonucleotides are useful for diagnostic applications involving sequence specific recognition of a nucleic acid and for use in a method of medical treatment.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: December 28, 2021
    Assignee: NOOGEN LLC
    Inventors: Dmitry Stetsenko, Maxim Kupryushkin, Dmitrii Pyshnyi
  • Patent number: 11202792
    Abstract: Provided herein are methods of treating a bone or connective tissue cancer in a subject. The methods comprise administering to the subject an effective amount of a CD99 inhibitor, wherein the CD99 inhibitor is a compound having the formula wherein R, each of which may be the same or different, is hydrogen, or a protecting group; wherein Z is selected from the group consisting of F, Cl and Br; wherein X is H or F; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: December 21, 2021
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Aykut Üren, Haydar Celik, Jeffrey A. Toretsky
  • Patent number: 11192914
    Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the nucleotide or nucleoside is defined by Formula I below,
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 7, 2021
    Assignee: Emory University
    Inventors: Gregory Bluemling, Abel De La Rosa, George Painter, Damien Kuiper, Alexander Kolykhalov
  • Patent number: 11180522
    Abstract: The present disclosure provides methods of sequencing polynucleotides and compounds, compositions useful for sequencing of polynucleotides. The chemical compounds include nucleotides and their analogs which possess a sugar moiety comprising a cleavable chemical group capping the 3?-OH group and a base that is attached to a label through a cleavable linker comprising a disulfide bond. In addition, both the disulfide bond and the cleavable chemical group are cleavable by a chemical reagent. Furthermore, after the disulfide bond is cleaved by the chemical reagent, there is no free thiol group linked to the base of the nucleotides according to the fragmentation reaction shown below as an example. Example compounds according to the present disclosure are shown as Formula (I): wherein w is 1-5; X is O, S, or BH3; B is a nucleotide base or an analog thereof, L1-3 are linkers; and D1 is a label.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: November 23, 2021
    Assignee: Centrillion Technology Holdings Corporation
    Inventors: Moti Jain, Kendall Hoff, Glenn McGall, Wei Zhou
  • Patent number: 11180520
    Abstract: Disclosed herein, inter alia, are methods for modifying a nucleotide, for example including reacting a nucleotide having a 3?-O-oxime moiety such as with a reagent having an —ONH2 moiety to produce a nucleotide having a 3?-O—NH2 moiety such as wherein the reagent having the —ONH2 moiety further comprises alkyl, alkenyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, or (heteroalicyclyl)alkyl.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: November 23, 2021
    Assignee: OMNIOME, INC.
    Inventors: Denis Malyshev, Aaron W. Feldman
  • Patent number: 11142545
    Abstract: The invention herein describes a solid-phase synthetic method for preparing thiolated oligonucleotides without needing a capping step. The methods of the invention comprises repetition of a three-reaction per cycle, namely detritylation, coupling and sulfurization, without a capping step. In some embodiments, the synthetic methods of the present invention can be used for preparing an anti-sense oligonucleotide.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: October 12, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Xianglin Shi, Jimin Yang, William F. Kiesman, Yannick Fillon
  • Patent number: 11110114
    Abstract: The present disclosure relates to novel dinucleotides comprising at least two locked nucleosides, one of which is directly attached to the 3? end of the triazole linker moiety and the other of which is directly linked to the 5? end of the triazole linker moiety and that are useful for the preparation of oligonucleotides. The disclosed dinucleotides may be used in gene therapy.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: September 7, 2021
    Assignee: Oxford University Innovation Limited
    Inventors: Tom Brown, Afaf Helmy El-Sagheer, Pawan Kumar
  • Patent number: 11104700
    Abstract: The present invention relates to novel oligonucleotides comprising at least one locked nucleoside and at least one triazole inter-nucleoside linkage linkage of Formula A or Formula B and methods of making the same.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: August 31, 2021
    Assignee: Oxford University Innovation Limited
    Inventors: Tom Brown, Afaf Helmy El-Sagheer, Pawan Kumar
  • Patent number: 11104899
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: August 31, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • Patent number: 11096979
    Abstract: Disclosed is a composition containing a licorice extract comprising glycyrrhizin and liquiritin at a content ratio of 1.5 to 1.8:1, obtained by performing extraction on licorice, adding an excipient and performing spray drying. The composition containing the licorice extract can be efficiently used as a pharmaceutical composition for the prevention or treatment of liver disease or a food composition for the improvement of liver function in the pharmaceutical and food industry fields.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 24, 2021
    Assignee: NOVAREX CO., LTD.
    Inventors: Suk-Hyung Kwon, Jae-Chul Jung, Kyung-Mi Kim
  • Patent number: 11084876
    Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 10, 2021
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer